Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Similarly, markers of mineral metabolism, such as PTH, iFGF23, Vitamin D (1,25OH and 25OH), magnesium (Mg), Ca, or P, remained unchanged.

Source: 2.2.1. Kidney Function and Mineral Metabolism Parameters in Patients with CKD and VC. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Open-label reported · Mixed research settings

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We aimed to evaluate the impact of a commercial probiotic (Probimel) supplementation on kidney function, mineral metabolism, inflammation and VC in both an experimental rat model and patients with advanced CKD and VC.

Source: Abstract.

In this randomized, open-label, parallel-group clinical trial, all subjects signed the informed consent form before inclusion in the study after the nature of the procedure had been fully explained to them.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Probiotic Supplementation in Chronic Kidney Disease: Outcomes on Uremic Toxins, Inflammation, and Vascular Calcification from Experimental and Clinical Models

Study design awaiting verification · Toxins · 2025

Original publication title

Probiotic Supplementation in Chronic Kidney Disease: Outcomes on Uremic Toxins, Inflammation, and Vascular Calcification from Experimental and Clinical Models

Teresa Obrero; María Victoria Pendón-Ruiz de Mier; Jose E. Gordillo-Arnaud; María José Jiménez Moral; Victoria Vidal; Fátima Guerrero; Andrés Carmona; María Encarnación Rodríguez-Ortiz; Ana Isabel Torralbo; Raquel Ojeda; Cayetana Moyano; Mercedes Sanchez-Ramade; Juan Mesa; Daniel J. López-Ruiz; Karen Valdés-Díaz; Raquel María García-Sáez; Daniel Jurado-Montoya; Cristian Rodelo-Haad; María Álvarez-Benito; Griet Glorieux; Mariano Rodríguez; Sagrario Soriano-Cabrera; Juan Rafael Muñoz-Castañeda

© 2025 by the authors.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Chronic kidney disease (CKD) is associated with gut microbiota alterations that contribute to increased inflammation and the generation of uremic toxins and may worsen the disease progression. While probiotics may improve the pro-inflammatory cytokine profile, their effects on mineral metabolism, vascular calcification (VC), and CKD progression remain unclear. We aimed to evaluate the impact of a commercial probiotic (Probimel) supplementation on kidney function, mineral metabolism, inflammation and VC in both an experimental rat model and patients with advanced CKD and VC.

The experimental model of VC was performed through 5/6 nephrectomy (Nx), a high-phosphate diet, and calcitriol. Animals were divided into three groups: Sham, Nephrectomy, and Nephrectomy + Probiotic. In the exploratory clinical study, 23 patients with advanced stage 5 CKD and VC were randomized and either received or did not receive daily probiotics for 6 months. Kidney function, mineral metabolism, uremic toxins, inflammation, VC, and fecal microbiota were evaluated. Probiotic supplementation decreased interleukin-6 (IL-6) and interpheron-γ (IFN-γ) and levels of the uremic toxin, indoxyl sulfate (IS), in the experimental model.

However, no clear evidence of improvement in kidney function or vascular calcification was observed in either rats or patients with this probiotic. Under our experimental and clinical conditions, the selected probiotic did not modify key parameters related to CKD progression or VC.

Authors’ abstract

Chronic kidney disease (CKD) is associated with gut microbiota alterations that contribute to increased inflammation and the generation of uremic toxins and may worsen the disease progression. While probiotics may improve the pro-inflammatory cytokine profile, their effects on mineral metabolism, vascular calcification (VC), and CKD progression remain unclear. We aimed to evaluate the impact of a commercial probiotic (Probimel) supplementation on kidney function, mineral metabolism, inflammation and VC in both an experimental rat model and patients with advanced CKD and VC.

The experimental model of VC was performed through 5/6 nephrectomy (Nx), a high-phosphate diet, and calcitriol. Animals were divided into three groups: Sham, Nephrectomy, and Nephrectomy + Probiotic. In the exploratory clinical study, 23 patients with advanced stage 5 CKD and VC were randomized and either received or did not receive daily probiotics for 6 months. Kidney function, mineral metabolism, uremic toxins, inflammation, VC, and fecal microbiota were evaluated. Probiotic supplementation decreased interleukin-6 (IL-6) and interpheron-γ (IFN-γ) and levels of the uremic toxin, indoxyl sulfate (IS), in the experimental model.

However, no clear evidence of improvement in kidney function or vascular calcification was observed in either rats or patients with this probiotic. Under our experimental and clinical conditions, the selected probiotic did not modify key parameters related to CKD progression or VC.

Publication and source details

Original title: Probiotic Supplementation in Chronic Kidney Disease: Outcomes on Uremic Toxins, Inflammation, and Vascular Calcification from Experimental and Clinical Models

Teresa Obrero; María Victoria Pendón-Ruiz de Mier; Jose E. Gordillo-Arnaud; María José Jiménez Moral; Victoria Vidal; Fátima Guerrero; Andrés Carmona; María Encarnación Rodríguez-Ortiz; Ana Isabel Torralbo; Raquel Ojeda; Cayetana Moyano; Mercedes Sanchez-Ramade; Juan Mesa; Daniel J. López-Ruiz; Karen Valdés-Díaz; Raquel María García-Sáez; Daniel Jurado-Montoya; Cristian Rodelo-Haad; María Álvarez-Benito; Griet Glorieux; Mariano Rodríguez; Sagrario Soriano-Cabrera; Juan Rafael Muñoz-Castañeda

Toxins · 2025

* Correspondence: teresa.obrero@imibic.org (T.O.); marias.soriano.sspa@juntadeandalucia.es (S.S.-C.); juanr.munoz.exts@juntadeandalucia.es (J.R.M.-C.)
†

These authors contributed equally to this work.

‡

These authors also contributed equally to this work.

© 2025 by the authors.2025https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.Instituto de Salud Carlos III (ISCIII)PI20/00781European UnionThis research was funded by a Spanish government grant from Instituto de Salud Carlos III (ISCIII) grants PI20/00781 co-funded by the European Union.

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T00:35:52.294025+00:00

DOI: 10.3390/toxins18010006 · PMC12846724